Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan sued in US court over generic Caduet ANDA

This article was originally published in Scrip

Executive Summary

Pfizer has filed suit in a US district court in Delaware against Mylan, alleging patent infringement related to its generic version of the single pill Caduet, a combination of lipid-lowering Lipitor (atorvastatin) and the antihypertensive Norvasc (amlodipine besylate). Pfizer seeks to protect its franchise, and alleges infringement of US patent No 6,455,574, which is set to expire in August 2018.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC006798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel